Correlation of serum and ascitic IL-12 levels with second-look laparotomy results and disease progression in advanced epithelial ovarian cancer patients

Bozkurt N., Yuce K., Basaran M., Gariboglu S., Kose F., Ayhan A.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, cilt.16, sa.1, ss.83-86, 2006 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 1
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1111/j.1525-1438.2006.00464.x
  • Dergi Adı: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.83-86
  • Anahtar Kelimeler: ascites, interleukin-12, ovarian cancer, prognosis, serum, IMMUNE-RESPONSES, IN-VIVO, INTERLEUKIN-12, THERAPY, LYMPHOCYTES, ANTITUMOR, IMMUNOTHERAPY, ANGIOGENESIS, SUPPRESSION, INHIBITION
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Forty-two consecutive patients with advanced epithelial ovarian cancer who underwent primary surgical treatment were evaluated. The control group comprised 21 patients who had undergone surgery associated with benign pathologies. Forty-one patients had stage III disease except one who had stage IV. Optimal debulking (< 1 cm) was performed in all the patients who subsequently received chemotherapy. Based on the results of the second-look laparotomy and follow-up, the patients were divided into three groups: the first group had negative second-look laparotomy or no evidence of disease during follow-up (n=21), the second group had positive second-look laparotomy or progressive disease (n=21), and the third was the control group (n=21). Interleukin-12 (IL-12) levels were measured in preoperative serum and intraoperative ascites samples for all the patients. The mean serum IL-12 levels (+/- SD) in serum (S) and ascites (A) were as follows: in the first group, S: 108.44 +/- 76.40 pg/mL and A: 330.93 +/- 125.25 pg/mL; in the second group, S: 51.80 +/- 40.95 pg/mL and A: 206.89 +/- 113.47 pg/mL; and in the control group, S: 36.55 +/- 33.16 pg/mL and A: 93.62 +/- 73.07 pg/mL (P=0.01). In the patients with advanced ovarian cancer, IL-12 levels in serum and ascites were higher compared to the levels of the controls. Also, there was an inverse relationship between initial serum and ascitic IL-12 levels and disease progression.